2517-04-6 Usage
Description
Azetidine-2-carboxylic acid is a heterocyclic amino acid that is not found in proteins but can be produced through the biosynthesis of the non-proteinogenic amino acid proline. It serves as an intermediate in the biosynthesis of the neurotransmitter gamma-aminobutyric acid (GABA) and has demonstrated potential pharmaceutical applications. Its versatile properties, including anti-tumor, anti-viral, and enzyme inhibitory activities, along with its potential in treating tinnitus and diabetes, make it a valuable compound for further research and development.
Uses
Used in Pharmaceutical Industry:
Azetidine-2-carboxylic acid is used as a pharmaceutical intermediate for its potential in the development of drugs targeting various diseases. Its anti-tumor properties make it a candidate for cancer treatment, while its anti-viral characteristics suggest potential applications in antiviral therapies.
Used in Enzyme Inhibition:
Azetidine-2-carboxylic acid is used as a potent inhibitor of various enzymes, which can be leveraged in the development of treatments for enzyme-related disorders and conditions.
Used in Neurotransmitter Research:
As an intermediate in the biosynthesis of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the central nervous system, azetidine-2-carboxylic acid is used in research to understand and potentially modulate GABAergic signaling, which could have implications for the treatment of neurological disorders.
Used in Tinnitus Treatment:
Azetidine-2-carboxylic acid is being investigated for its potential in the treatment of tinnitus, a condition characterized by the perception of sound without an external source, suggesting its use as a therapeutic agent for auditory disorders.
Used in Diabetes Management:
Research into the potential of azetidine-2-carboxylic acid in diabetes treatment highlights its use as a compound that could contribute to the management or treatment of this metabolic disease, possibly through its effects on insulin sensitivity or glucose metabolism.
Check Digit Verification of cas no
The CAS Registry Mumber 2517-04-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,5,1 and 7 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 2517-04:
(6*2)+(5*5)+(4*1)+(3*7)+(2*0)+(1*4)=66
66 % 10 = 6
So 2517-04-6 is a valid CAS Registry Number.
InChI:InChI=1/C4H7NO2/c6-4(7)3-1-2-5-3/h3,5H,1-2H2,(H,6,7)
2517-04-6Relevant articles and documents
Synthesis of 2-carboxylated aza-ring derivatives through α-monohalogenation/ring-contraction of N-sulfonyl lactams
Sirindil, Fatih,Miaskiewicz, Solène,Kern, Nicolas,Lalaut, Arno,Felten, Anne-Sophie,Weibel, Jean-Marc,Pale, Patrick,Blanc, Aurélien
, p. 5096 - 5106 (2017/07/28)
2-Carboxylated aza-rings have been synthesized in two steps through a highly selective monohalogenation of N-sulfonylated lactams of various ring sizes (from 5- to 8-membered rings) followed by a ring contraction reaction. The selective monohalogenation of N-sulfonyl lactams has been achieved in modest to excellent yields (9 examples, 39–96%) using N-halogenosuccinimides via the in situ generation of trimethylsilyl ketene aminal derivatives. The so-obtained α-halogeno N-sulfonyl lactams were engaged in a ring opening/ring closing reaction in the presence of various alcohols or anilines under basic conditions affording 2-carboxylated aza-rings, such as azetidine, pyrrolidine or piperidine derivatives in high yields (24 examples, 61–99%).
Anti-heparin peptides
-
, (2008/06/13)
The invention concerns a compound exhibiting an anti-heparin activity, of formula Z Bm ! (AXA)x Bn ! (AXA)y Bo (AXA)z Bp, the diagnostic reagents comprising it and the use of said compound in an in vitro diagnostic test of a medicine for anti-heparin activity.
Process for the production of enantiomerically-pure azetidine-2-carboxylic acid
-
, (2008/06/13)
The invention relates to a process for the production of enantiomerically-pure AzeOH which comprises selective crystallisation of a diastereomerically-pure tartrate salt thereof, followed by liberation of the free amino acid, as well as the compounds L-azetidine-2-carboxylic acid-D-tartrate and D-azetidine-2-carboxylic acid-L-tartrate.
